Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility

Gustavo Ferrín,1,2 Patricia Aguilar-Melero,1 Manuel Rodríguez-Perálvarez,1,2 José Luis Montero-Álvarez,1,2 Manuel de la Mata1,2 1Liver Unit, Instituto Maimónides de Investigación Biomédica de Córdoba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/16111fef4f1c40abab9a79c7b9443e3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16111fef4f1c40abab9a79c7b9443e3e
record_format	dspace
spelling	oai:doaj.org-article:16111fef4f1c40abab9a79c7b9443e3e2021-12-02T03:24:56ZBiomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility1179-1535https://doaj.org/article/16111fef4f1c40abab9a79c7b9443e3e2015-04-01T00:00:00Zhttp://www.dovepress.com/biomarkers-for-hepatocellular-carcinoma-diagnostic-and-therapeutic-uti-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535 Gustavo Ferrín,1,2 Patricia Aguilar-Melero,1 Manuel Rodríguez-Perálvarez,1,2 José Luis Montero-Álvarez,1,2 Manuel de la Mata1,2 1Liver Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain; 2Centro de Investigación Biomédica en Red (CIBER), Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain Abstract: Because of the high prevalence and associated-mortality of hepatocellular carcinoma (HCC), early diagnosis of the disease is vital for patient survival. In this regard, tumor size is one of the two main prognostic factors for surgical resection, which constitutes the only curative treatment for HCC along with liver transplantation. However, techniques for HCC surveillance and diagnosis that are currently used in clinical practice have certain limitations that may be inherent to the tumor development. Thus, it is important to continue efforts in the search for biomarkers that increase diagnostic accuracy for HCC. In this review, we focus on different biological sources of candidate biomarkers for HCC diagnosis. Although those biomarkers identified from biological samples obtained by noninvasive methods have greater diagnostic value, we have also considered those obtained from liver tissue because of their potential therapeutic value. To date, sorafenib is the only US Food and Drug Administration-approved antineoplastic for HCC. However, this therapeutic agent shows very low tumor response rates and frequently causes acquired resistance in HCC patients. We discuss the use of HCC biomarkers as therapeutic targets themselves, or as targets to increase sensitivity to sorafenib treatment. Keywords: diagnosis, sorafenib, therapyFerrín GAguilar-Melero PRodríguez-Perálvarez MMontero-Álvarez JLde la Mata MDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2015, Iss default, Pp 1-10 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Ferrín G Aguilar-Melero P Rodríguez-Perálvarez M Montero-Álvarez JL de la Mata M Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
description	Gustavo Ferrín,1,2 Patricia Aguilar-Melero,1 Manuel Rodríguez-Perálvarez,1,2 José Luis Montero-Álvarez,1,2 Manuel de la Mata1,2 1Liver Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain; 2Centro de Investigación Biomédica en Red (CIBER), Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain Abstract: Because of the high prevalence and associated-mortality of hepatocellular carcinoma (HCC), early diagnosis of the disease is vital for patient survival. In this regard, tumor size is one of the two main prognostic factors for surgical resection, which constitutes the only curative treatment for HCC along with liver transplantation. However, techniques for HCC surveillance and diagnosis that are currently used in clinical practice have certain limitations that may be inherent to the tumor development. Thus, it is important to continue efforts in the search for biomarkers that increase diagnostic accuracy for HCC. In this review, we focus on different biological sources of candidate biomarkers for HCC diagnosis. Although those biomarkers identified from biological samples obtained by noninvasive methods have greater diagnostic value, we have also considered those obtained from liver tissue because of their potential therapeutic value. To date, sorafenib is the only US Food and Drug Administration-approved antineoplastic for HCC. However, this therapeutic agent shows very low tumor response rates and frequently causes acquired resistance in HCC patients. We discuss the use of HCC biomarkers as therapeutic targets themselves, or as targets to increase sensitivity to sorafenib treatment. Keywords: diagnosis, sorafenib, therapy
format	article
author	Ferrín G Aguilar-Melero P Rodríguez-Perálvarez M Montero-Álvarez JL de la Mata M
author_facet	Ferrín G Aguilar-Melero P Rodríguez-Perálvarez M Montero-Álvarez JL de la Mata M
author_sort	Ferrín G
title	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
title_short	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
title_full	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
title_fullStr	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
title_full_unstemmed	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
title_sort	biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/16111fef4f1c40abab9a79c7b9443e3e
work_keys_str_mv	AT ferring biomarkersforhepatocellularcarcinomadiagnosticandtherapeuticutility AT aguilarmelerop biomarkersforhepatocellularcarcinomadiagnosticandtherapeuticutility AT rodriguezperalvarezm biomarkersforhepatocellularcarcinomadiagnosticandtherapeuticutility AT monteroalvarezjl biomarkersforhepatocellularcarcinomadiagnosticandtherapeuticutility AT delamatam biomarkersforhepatocellularcarcinomadiagnosticandtherapeuticutility
_version_	1718401778188288000

Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility

Ejemplares similares